


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of general formula I:



wherein:

$R^1$  represents hydrogen or  $C_{1-4}$  alkyl;

$R^2$  represents hydrogen or  $-C(=O)R^7$ ;

$R^3$  represents  $C_{1-5}$  fluoroalkyl,  $C_{2-5}$  fluoroalkenyl or  $C_{2-5}$  fluoroalkynyl;

$R^4$ ,  $R^5$  and  $R^6$  independently represent hydrogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, halogen, cyano, hydroxy, nitro,  $-NR^8R^9$ ,  $-S(O)_xR^{10}$  or  $-C(=O)R^{11}$ ;

$R^7$  and  $R^{10}$  independently represent  $C_{1-4}$  alkyl;

$R^8$ ,  $R^9$  and  $R^{11}$  independently represent hydrogen or  $C_{1-4}$  alkyl; and  $x$  represents 0, 1 or 2;

with the proviso that when  $R^1$  represents methyl,  $R^2$  represents hydrogen,  $R^3$  represents 1,1,2,2-tetrafluoroethyl and  $R^4$  and  $R^5$

represent hydrogen then R<sup>6</sup> cannot be hydroxy, and with the further proviso that when R<sup>1</sup> represents hydrogen, R<sup>2</sup> represents hydrogen and R<sup>3</sup> represents 3-fluoropropyl then R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> cannot represent simultaneously fluoro;

~~and the~~ or a salts, solvates ~~and~~ or prodrugs thereof.

2. (Original) A compound according to claim 1 wherein R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> represent hydrogen.

3. (Original) A compound according to claim 1 or 2 wherein R<sup>3</sup> represents C<sub>1-5</sub> fluoroalkyl.

4. (Original) A compound according to claim 1 or 2 wherein R<sup>3</sup> represents C<sub>1-3</sub> fluoroalkyl, C<sub>2-3</sub> fluoroalkenyl or C<sub>2-3</sub> fluoroalkynyl.

5. (Original) A compound according to claim 1 or 2 wherein R<sup>3</sup> represents C<sub>1-3</sub> fluoroalkyl.

6. (Original) A compound according to claim 1 or 2 wherein R<sup>3</sup> represents 2,2,3,3,3-pentafluoropropyl.

7. (Currently amended) A compound according to ~~any of claims 1 to 6~~ claim 1 or 2 wherein R<sup>1</sup> represents hydrogen.

8. (Currently amended) A compound according to ~~any of claims 1 to 7~~ claim 1 or 2 wherein R<sup>2</sup> represents hydrogen or acetyl.

9. (Currently amended) A compound according to claim 1 selected from:

methyl 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoate;


methyl 2-hydroxy-4-(2,2,2-trifluoroethoxy)benzoate;  
methyl 2-hydroxy-4-(2,2,3,3-tetrafluoropropoxy)benzoate;  
methyl 2-hydroxy-4-(2-fluoroethoxy)benzoate;  
methyl 4-(2,2-difluoroethoxy)-2-hydroxybenzoate;  
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid;  
2-hydroxy-4-(2,2,2-trifluoroethoxy)benzoic acid;  
2-hydroxy-4-(2,2,3,3-tetrafluoropropoxy)benzoic acid;  
2-hydroxy-4-(2-fluoroethoxy)benzoic acid;  
4-(2,2-difluoroethoxy)-2-hydroxybenzoic acid;  
2-acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid; and  
2-acetoxy-4-(2-fluoroethoxy)benzoic acid;  
~~or~~ and a salt, solvate or prodrug thereof.

10. (Currently amended) 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid ~~and the~~ or a salts, solvates ~~and~~ or prodrugs thereof.

11. (Currently amended) 2-Acetoxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid ~~and the~~ or a salts, solvates ~~and~~ or prodrugs thereof.

12-13. (Canceled)

14. (Currently amended) A pharmaceutical composition which comprises an effective amount of a compound of formula I



I

wherein:

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> represents hydrogen or -C(=O)R<sup>7</sup>;

R<sup>3</sup> represents C<sub>1-5</sub> fluoroalkyl, C<sub>2-5</sub> fluoroalkenyl or C<sub>2-5</sub> fluoroalkynyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, halogen, cyano, hydroxy, nitro, -NR<sup>8</sup>R<sup>9</sup>, -S(O)<sub>x</sub>R<sup>10</sup> or -C(=O)R<sup>11</sup>;

R<sup>7</sup> and R<sup>10</sup> independently represent C<sub>1-4</sub> alkyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl; and

x represents 0, 1 or 2;


with the proviso that when R<sup>1</sup> and R<sup>2</sup> each represents hydrogen, and R<sup>3</sup> represents 3-fluorophenyl, then R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> simultaneously cannot represent fluoro;

or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more pharmaceutically acceptable excipients.

15. (Original) A pharmaceutical composition according to claim 14 further comprising one or more additional drugs.

16. (Original) A pharmaceutical composition according to claim 14 further comprising one or more chemotherapeutic agents.

17. (Currently amended) A product comprising a compound of formula I



I

wherein:

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> represents hydrogen or -C(=O)R<sup>7</sup>;

R<sup>3</sup> represents C<sub>1-5</sub> fluoroalkyl, C<sub>2-5</sub> fluoroalkenyl or C<sub>2-5</sub> fluoroalkynyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, halogen, cyano, hydroxy, nitro, -NR<sup>8</sup>R<sup>9</sup>, -S(O)<sub>x</sub>R<sup>10</sup> or -C(=O)R<sup>11</sup>;

R<sup>7</sup> and R<sup>10</sup> independently represent C<sub>1-4</sub> alkyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl; and

x represents 0, 1 or 2;

with the proviso that when R<sup>1</sup> and R<sup>2</sup> each represents hydrogen,

and R<sup>3</sup> represents 3-fluorophenyl, then R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>


simultaneously cannot represent fluoro;

or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more additional drugs, as a combined preparation for simultaneous, sequential or separate use.

18. (Original) A product according to claim 17 wherein the additional drug is a chemotherapeutic agent.

19. (Currently amended) A method of treating or preventing immune diseases which comprises administering to a subject in need thereof an effective amount of use of a compound of formula

I



I

wherein:

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> represents hydrogen or -C(=O)R<sup>7</sup>;

R<sup>3</sup> represents C<sub>1-5</sub> fluoroalkyl, C<sub>2-5</sub> fluoroalkenyl or C<sub>2-5</sub> fluoroalkynyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, halogen, cyano, hydroxy, nitro, -NR<sup>8</sup>R<sup>9</sup>, -S(O)<sub>x</sub>R<sup>10</sup> or -C(=O)R<sup>11</sup>;


R<sup>7</sup> and R<sup>10</sup> independently represent C<sub>1-4</sub> alkyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl; and  
x represents 0, 1 or 2;

or a pharmaceutically acceptable salt, solvate or prodrug thereof  
~~for the manufacture of a medicament for the treatment or~~  
~~prevention of immune diseases.~~

20. (Currently amended) A method ~~Use~~ according to claim  
19 wherein the immune disease is selected from the group  
consisting of psoriasis, ~~other skin diseases such as~~ atopic  
dermatitis, contact dermatitis, lichen planus, dermatomyositis,  
scleroderma, erythema multiforme, urticaria, ~~and~~ pemphigus,  
inflammatory bowel disease, ~~including Crohn's disease and~~  
~~ulcerative colitis,~~ rheumatoid arthritis, ~~and other arthritic~~  
~~diseases such as~~ gouty arthritis, psoriatic arthritis, juvenile  
arthritis, ~~and~~ ankylosing spondylitis, multiple sclerosis ~~and~~  
~~other autoimmune neuropathies,~~ diabetes, transplant rejection,  
graft-versus-host disease, lupus erythematosus, vasculitis,  
Sjögren's syndrome, Guillain-Barre syndrome, glomerulonephritis,  
~~respiratory diseases such as~~ allergic rhinitis, asthma, fibrosis, ~~and~~  
~~and~~ chronic obstructive pulmonary disease, and neoplasias with  
proliferation of immune cells.

21. (Currently amended) ~~Use of~~ A method of treating or  
preventing cancer which comprises administering to a subject in  
need thereof a compound of formula I



I

wherein:

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> represents hydrogen or -C(=O)R<sup>7</sup>;

R<sup>3</sup> represents C<sub>1-5</sub> fluoroalkyl, C<sub>2-5</sub> fluoroalkenyl or C<sub>2-5</sub> fluoroalkynyl;

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, halogen, cyano, hydroxy, nitro, -NR<sup>8</sup>R<sup>9</sup>, -S(O)<sub>x</sub>R<sup>10</sup> or -C(=O)R<sup>11</sup>;

R<sup>7</sup> and R<sup>10</sup> independently represent C<sub>1-4</sub> alkyl;

R<sup>8</sup>, R<sup>9</sup> and R<sup>11</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl; and


x represents 0, 1 or 2;

or a pharmaceutically acceptable salt, solvate or prodrug thereof

~~for the manufacture of a medicament for the treatment or prevention of cancer.~~

22. (Currently amended) Process for preparing a compound of formula I,





I

wherein:

$\text{R}^1$  represents hydrogen or  $\text{C}_{1-4}$  alkyl;

$\text{R}^2$  represents hydrogen or  $\text{-C(=O)R}^7$ ;

$\text{R}^3$  represents  $\text{C}_{1-5}$  fluoroalkyl,  $\text{C}_{2-5}$  fluoroalkenyl or  $\text{C}_{2-5}$  fluoroalkynyl;

$\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  independently represent hydrogen,  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  haloalkyl,  $\text{C}_{1-4}$  alkoxy,  $\text{C}_{1-4}$  haloalkoxy, halogen, cyano, hydroxy, nitro,  $\text{-NR}^8\text{R}^9$ ,  $\text{-S(O)}_x\text{R}^{10}$  or  $\text{-C(=O)R}^{11}$ ;


$\text{R}^7$  and  $\text{R}^{10}$  independently represent  $\text{C}_{1-4}$  alkyl;

$\text{R}^8$ ,  $\text{R}^9$  and  $\text{R}^{11}$  independently represent hydrogen or  $\text{C}_{1-4}$  alkyl; and

$x$  represents 0, 1 or 2;

which comprises:


(a) reacting a phenol of formula II



II

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the meaning described above, with an alkylating agent of formula G-R<sup>3</sup> (III), wherein R<sup>3</sup> has the meaning described above and G represents a leaving group; or  
(b) ~~converting, in one or more steps,~~ a compound of formula I into another compound of formula I; and  
(c) optionally, if desired, after the above steps and when R<sup>1</sup> and/or R<sup>2</sup> represent hydrogen, reacting a compound of formula I with a base, to obtain the corresponding addition salt.

23. (New) A compound of general formula I:



I

wherein:

R<sup>1</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

$R^2$  represents hydrogen or  $-C(=O)R^7$ ;

$R^3$  represents  $C_{1-5}$  fluoroalkyl,  $C_{2-5}$  fluoroalkenyl or  $C_{2-5}$  fluoroalkynyl;

$R^4$ ,  $R^5$  and  $R^6$  independently represent hydrogen,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, halogen, cyano, hydroxy, nitro,  $-NR^8R^9$ ,  $-S(O)_xR^{10}$  or  $-C(=O)R^{11}$ ;

$R^7$  and  $R^{10}$  independently represent  $C_{1-4}$  alkyl;

$R^8$ ,  $R^9$  and  $R^{11}$  independently represent hydrogen or  $C_{1-4}$  alkyl; and

$x$  represents 0, 1 or 2;

with the proviso that when  $R^1$  represents methyl,  $R^2$  represents hydrogen,  $R^3$  represents 1,1,2,2-tetrafluoroethyl and  $R^4$  and  $R^5$  represent hydrogen then  $R^6$  cannot be hydroxy, and with the further proviso that when  $R^1$  represents hydrogen,  $R^2$  represents hydrogen and  $R^3$  represents 3-fluoropropyl then  $R^4$ ,  $R^5$  and  $R^6$  cannot represent simultaneously fluoro.

24. (New) 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid.